Opinion|Videos|January 20, 2025
Evolving Paradigms, CAR T, and Treatment Selection in Early-Stage R/R MM
Author(s)Amrita Krishnan, MD
The panelist discusses how the treatment landscape for early-stage relapsed/refractory multiple myeloma (R/R MM) has evolved significantly with CAR T-cell therapies (idecabtagene vicleucel, ciltacabtagene autoleucel [ide-cel, cilta-cel]) and novel drug combinations. Treatment selection now considers prior therapies, patient characteristics, and response duration. For third-line chimeric antigen receptor (CAR) T after no prior CAR T use, cilta-cel shows favorable efficacy data with deeper, more durable responses than ide-cel, though both are viable options.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How has the treatment landscape evolved for patients with early-stage R/R MM?
- How has the evolving paradigm affected your approach to treatment selection and sequencing in early-stage R/R MM?
- For patients not previously treated with CAR T in the second line (2L), what choice of CAR T therapy would you consider in the 3L setting?
- What factors inform your selection of CAR T beyond the 2L setting in MM?
- What lessons have you learned from bridging therapy, and how would you advise on optimal strategies?
Advertisement
Related to this article
The UK's OPTIMUM trial showed significant differences with a more aggressive treatment regimen for high-risk newly diagnosed multiple myeloma, based on long-term follow-up.
During a live Case-Based Roundtable event, Brea Lipe, MD, and participants discussed treatment options for an older patient who already received multiple bispecific antibodies for multiple myeloma.
In the pivotal phase 2 QUINTESSENTIAL trial, arlo-cel, a GPRC5D-targeted CAR T-cell therapy, showed favorable overall response rate in patients who had received multiple prior lines including BCMA-targeted therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Daraxonrasib Combo Receives FDA Breakthrough Status in First-Line PDAC
2
Sacituzumab Govitecan Combo Misses PFS End Point in PD-L1–High NSCLC
3
T-DXd Significantly Improves PFS in First-Line HER2-Mutant NSCLC
4
Amivantamab-Chemotherapy Shows Longest OS Reported in EGFR Exon 20 NSCLC
5